CompletedPhase 2NCT02767531
Orlistat for the Treatment of Type I Hyperlipoproteinemia
Studying Familial lipoprotein lipase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Texas Southwestern Medical Center
- Principal Investigator
- Abhimanyu Garg, MDUniversity of Texas
- Intervention
- Orlistat(drug)
- Enrollment
- 2 enrolled
- Eligibility
- 8-18 years · All sexes
- Timeline
- 2015 – 2022
Study locations (1)
- UT Southwestern Medical Center 5323 Harry Hines Blvd, Dallas, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02767531 on ClinicalTrials.govOther trials for Familial lipoprotein lipase deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07371767CS-121 APOC3 Base Editing in Children and Adolescents With HyperchylomicronemiaShanghai Jiao Tong University School of Medicine
- RECRUITINGEARLY PHASE1NCT07176923CS-121 APOC3 Base Editing in FCSCorrectSequence Therapeutics Co., Ltd
- ACTIVE NOT RECRUITINGPHASE3NCT05185843A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With VolanesorsenIonis Pharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGPHASE3NCT05130450A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)Ionis Pharmaceuticals, Inc.
- RECRUITINGNANCT04227678Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase DeficiencyUniversité de Sherbrooke